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Abstract
Background: Cellular cobalamin defects are a locus and allelic heterogeneous disorder. The gold standard for
coming to genetic diagnoses of cobalamin defects has for some time been gene-by-gene Sanger sequencing of
individual DNA fragments. Enzymatic and cellular methods are employed before such sequencing to help in the
selection of the gene defects to be sought, but this is time-consuming and laborious. Furthermore some cases
remain undiagnosed because no biochemical methods have been available to test for cobalamin absorption and
transport defects.
Results: This paper reports the use of massive parallel sequencing of DNA (exome analysis) for the accurate and
rapid genetic diagnosis of cobalamin-related defects in a cohort of affected patients. The method was first validated
in an initial cohort with different cobalamin defects. Mendelian segregation, the frequency of mutations, and the
comprehensive structural and functional analysis of gene variants, identified disease-causing mutations in 12 genes
involved in the absorption and synthesis of active cofactors of vitamin B12 (22 cases), and in the non-cobalamin
metabolism-related genes ACSF3 (in four biochemically misdiagnosed patients) and SUCLA2 (in one patient with an
unusual presentation). We have identified thirteen new variants all classified as pathogenic according to the ACGM
recommendation but four were classified as variant likely pathogenic in MUT and SUCLA2. Functional and structural
analysis provided evidences to classify them as pathogenic variants.
Conclusions: The present findings suggest that the technology used is sufficiently sensitive and specific, and the
results it provides sufficiently reproducible, to recommend its use as a second-tier test after the biochemical
detection of cobalamin disorder markers in the first days of life. However, for accurate diagnoses to be made,
biochemical and functional tests that allow comprehensive clinical phenotyping are also needed.
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Background
Cellular cobalamin problems are caused by nutritional de-
ficiency or genetic defects that affect either the absorption
or cellular uptake of the vitamin or the synthesis from it
of methylcobalamin (MeCbl) and adenosylcobalamin
(AdoCbl). The latter are, respectively, a cofactor of me-
thionine synthase (MS EC_2.1.1.13), which catalyzes the
remethylation of homocysteine (Hcys) to methionine in
the cytoplasm, and of methylmalonyl-CoA mutase (MUT
EC_5.4.99.2), which catalyzes the mitochondrial isomeri-
zation of L-methylmalonyl-CoA (MMACoA) to succinyl-
CoA. Defects in the synthesis of AdoCbl or the conversion
of MMACoA to succinyl-CoA lead to elevated methylma-
lonic acid (MMA) concentrations, while defects in the
synthesis of MeCbl or the remethylation of Hcys to me-
thionine cause elevated Hcys (HC). Defects in the absorp-
tion and transport of vitamin B12, and in the cytosolic
synthesis of the above cofactors, cause methylmalonic
aciduria with homocystinuria (MMA&HC) [1, 2].
After its intake, cobalamin is first bound to haptocor-
rin (encoded by TCN1) and then to the intrinsic factor
(IF) encoded by GIF. To date, only one pathogenic mu-
tation and one functional polymorphism (p.Asp301Tyr
in TCN1) have been described [3, 4]. Cubilin and
amnionless, encoded by CUBN and AMN respectively,
form the cubam dimer which functions as the receptor
of IF-Cbl in the ileum [4]. The IF is then degraded and
vitamin B12 appears in the blood stream associated with
transcobalamin II (TCII) [2, 5]. Inherited malabsorption
of cobalamin causes haematological and neurological ab-
normalities that can be fatal [6].
Still bound to TCII, the vitamin enters cells via trans-
cobalamin receptor (TCblR)-mediated endocytosis. This
receptor is encoded by CD320, for which only one muta-
tion has been described [7]. The cobalamin is then re-
leased into the cytosol, an event impaired in people with
defects in LMBRD1 (cblF complementation group, MIM
#277380) [8]. LMBRD1 protein interacts with ABCD4
protein, which is also involved in the release of Cbl into
the cytoplasm from the lysosomes (a defect which falls
into complementation group cblJ) [9]. The most com-
mon form of cobalamin defect, complementation group
cblC (MIM#277400), is caused by mutations affecting
MMACHC [10]. Patients with mutations in the Host Cell
Factor 1 (HCFC1) locus (MIM 309541), located on the X
chromosome, have a phenocopy of cblC disease [11]
since HCFC1 encodes a transcriptional co-regulator of
MMACHC. Recently additional defects have been de-
scribed that affect transcription factors involved in the
regulation of Cbl pathway: ZNF143 [12] and THAP11
[13]. In addition new variants in PRDX1 also affect the
expression of MMACHC, named epi-cblC cases. Thus,
these patients result from pathogenic variants in
MMACHC and one in PRDX1 which force the antisense
transcription of MMACHC and thereby a possible
methylation mark [14].
Cellular cobalamin processing occurs via two major
pathways - the cytosolic and mitochondrial pathways.
The protein thought to be responsible for sorting
cobalamin for these pathways is MMADHC (cblD
complementation group, MIM #611935). This com-
plementation group is the most complex of all since
patients present with biochemical heterogeneity ran-
ging from isolated homocystinuria (cblD variant 1)
or isolated methylmalonic aciduria (cblD variant 2)
through to methylmalonic aciduria combined with
homocystinuria (cblD) depending on the nature and
location of the mutations present [15].
The cytosolic pathway is involved in the synthesis of
MeCbl by MS, encoded by MTR (defects give rise to
complementation group cblG), while the enzyme me-
thionine synthase reductase encoded by MTRR is in-
volved in the reactivation of MS (defects give rise to
complementation group cblE). Both cblG (MIM#250940)
and cblE (MIM#236270) defects, lead to elevated Hcys,
hypomethioninaemia, and megaloblastic anaemia [1, 2].
Inactive cob(II)alamin entering the mitochondria is
converted into AdoCbl via a reductive adenosylation
reaction catalysed by an adenosyltransferase (ATR)
encoded at the cblB locus (MIM#251110) [16]. MUT is
encoded at the MUT locus and two different phenotypes
have been described: mut0 and mut− (MIM#251100). Fi-
nally MMAA is the gene associated with complementa-
tion group cblA defects (MIM# 607481). It encodes a
protein of the same name which may be involved in
transferring AdoCbl from ATR to MUT protein as well
as maintaining MUT’s functional integrity [5, 17].
Mildly elevated MMA also occurs in patients with mu-
tations affecting SUCLA2 (MIM#612073) and SUCLG1
(MIM#245400) which lead to infantile mitochondrial en-
cephalopathic depletion syndrome. These genes encode
either the ß-subunit of ADP-forming or the α-subunit of
GDP-forming succinyl-CoA synthetases. The accumu-
lated succinyl-CoA inhibits the metabolism of MMA-
CoA to succinyl-CoA, leading to the accumulation of
MMA in body fluids. Mutations in SUCLA2 give rise to
typical (though rare) early onset dystonia combined with
deafness [18, 19]. An increase in MMA is also seen in
patients with mutations in ACSF3 (MIM# 614265), in
whom malonic acid levels may also be elevated (com-
bined malonic and methylmalonic aciduria, CMAMMA)
[20]. ACSF3 encodes a mitochondrial acyl-CoA synthe-
tase considered to have malonyl-CoA and MMACoA
synthetase activities.
The diagnosis of an intracellular cobalamin metabol-
ism disorder in a symptomatic individual is based on
both clinical suspicion and biochemical analyses [1, 21].
Since expanded newborn screening potentially allows
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early detection of certain disorders of intracellular co-
balamin metabolism, some affected individuals may be
diagnosed prior to the onset of clinical symptoms. Diag-
nosis is based on elevated propionylcarnitine (C3), a
high propionylcarnitine to acetylcarnitine ratio (C3/C2),
high heptadecanoylcarnitine (C17), and/or reduced
methionine concentrations [22]. After symptomatic or
asymptomatic detection, a differential diagnosis is
needed to help identify the gene that might be involved.
Confirmatory testing is based on measuring Hcys and
MMA in plasma and/or urine, enzyme analyses, the in-
corporation of [1-14C] propionate and [5-14C] methyl-
THF into proteins in fibroblasts cultured in basal and
hydroxocobalamin-supplemented media, and in some
cases by cellular complementation assays [1]. However,
biochemical analysis cannot pinpoint a genetic defect,
making diagnosis complicated. Fortunately, recent devel-
opments in high-throughput sequence capture have
made next generation sequencing (NGS) a rapid and ac-
curate means of analysing genetic locus and allele het-
erogeneous disorders [23–25].
The main purpose of clinical laboratory testing is to
support medical decision-making. Clinical genetic testing
is generally used to identify or confirm the cause of a dis-
ease and, if possible, to provide ideas for personalized
treatment. Massive parallel sequencing is the starting
point of a complex process for identifying pathogenic vari-
ants as well as the description of new functions for a gene
product [25]. The aim of the present work was to assess
the use of genetic studies as second-tier tests following
the detection of cobalamin disorders in biochemical new-
born screening. The usefulness of massive parallel sequen-
cing in the identification of the mutated genes responsible
for cobalamin and related defects was analyzed, and the
structural and functional analysis of the novel variants
identified undertaken.
Methods
Patients
Patient-derived fibroblasts, blood samples or dried
blood spots from 27 patients with elevated MMA
and/or Hcys or vitamin B12 deficiency were referred
to our laboratory for genetic analysis. Another 9 sam-
ples from patients with cobalamin defects, previously
diagnosed in our laboratory, were included for valid-
ation purposes. The diagnosis of these cases was
made by biochemical, cellular and genetic studies.
Fourteen cases were detected through expanded new-
born screening programs; the others were diagnosed
after clinical presentation (neonatal or late onset).
The study was approved by the ethics committee of
the Universidad Autónoma de Madrid. The partici-
pants or their legal guardians gave their signed, in-
formed consent to be included.
Genetic analysis
High purity DNA was extracted from whole blood, fibro-
blasts or dried blood spot samples using the MagNA
Pure Compact Kit (Roche Applied Biosciences, Indian-
apolis, IN) following the manufacturer’s protocol. Two
massive parallel sequencing panels were used: targeted
customized exome sequencing to capture the exome of
120 genes involved in metabolic disorders (Nextera Na-
ture Capture, Illumina, San Diego, California, USA) (the
list of genes included can be sent upon request), and an
extended panel (Clinical-Exome Sequencing TruSight™
One Gene Panel, Illumina) that included all the known
(in 2013) disease-associated genes described in the
OMIM database (Mendeliome panel). For genetic ana-
lysis in the validation cohort both panels were used. For
genetic analysis in discovery cohort either of the two
panels was used, except in cases P24-P27 where both
panels were used. After gene capture and alignment with
the reference genome, variant callings were made using
a virtual panel that included all cobalamin metabolism
and related genes. Incidental findings in genes unrelated
to the clinical/biochemical phenotypes were ignored.
Additional files 1 and 2 describes the coverage of the
genes. With both panels, the libraries generated were se-
quenced using 150 bp paired-end reads employing the
Illumina MiSeq or Nextseq500 NGS platforms. SNVs
was annotated and subsequently filtered as previously
described [26]. Variants were always confirmed by con-
ventional Sanger sequencing employing both patient
genomic DNA and that of their parents if available.
Pathogenic prediction was assessed by Alamut Visual
software. Variants were classified following the ACMG
recommendation guidelines [27, 28].
Assessment of variant pathogenicity
To assess the isolated effect of the recently described
mutation c.1084-10A > G in MUT [29], the splicing pro-
file was analyzed ex vivo using a minigene assay. Briefly,
exon 6 and the corresponding flanking intronic regions
from patient P10 were amplified as previously described
and cloned into pSPL3 vector [30]. Transcriptional pro-
file analysis was performed as described elsewhere [30].
The oxygen consumption rate (OCR) was measured
using the XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, Billerica, MA, USA) as previously described
[31] in cells transduced with lentiviral particles incorpor-
ating wild-type cDNA of SUCLA2 (NM_003850) or the
respective negative control. Modulating compounds
such as oligomycin inhibitor of the ATP synthase (OL,
6 μM), carbonyl cyanide 4-(trifluoromethoxy) phenyl-
hydrazone a potent uncoupler of oxidative phosphoryl-
ation in mitochondria (FCCP, 50 μM), rotenone inhibitor
of complex I (RO, 1 μM) and antimycin A inhibitor of
complex III (AT, 1 μM) were used to assess the
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bioenergetic profile and were sequentially added to the
cells. The calibration plate for these compounds was
prepared according to the manufacturer’s protocol. The
data obtained were used to determine basal OCR, the
maximum respiratory rate, ATP-linked respiration, mito-
chondrial reserve capacity, proton leakage and
non-mitochondrial respiration. Briefly, for OCR determi-
nations, patient-derived skin fibroblasts (5 × 104 each),
were seeded per well in 24-well tissue culture micro-
plates and incubated with 100 μl DMEM supplemented
galactose (1 g/L g/l, DMEM-Gal) instead of glucose at
37 °C for 2–5 h. After the incubation period, up to
250 μl of the corresponding medium was added and in-
cubated overnight at 37 °C. On the next day, the
medium was removed and the cells washed with phos-
phate saline buffer (PBS). 700 μl of the corresponding
medium DMEM-Gal without bicarbonate were then
added and the plates incubated at 37 °C for 1 h.
Functional prediction
The novel intronic and exonic SNVs identified were ana-
lyzed using Alamut Visual software, which includes a
number of functional predictors. The two SUCLA2 vari-
ants (p.Gly326Arg, p.Ile312Thr) were mapped to a hom-
ology model of the human protein based on the known
X-ray structure of SUCLG2 (S. scrofa; PDB code: 2fp4)
[32]. The percentage sequence identity between these
proteins was 54% [33].
Results
Genetic analysis
To assess the sensitivity of the proposed assay in the de-
tection of pathogenic mutations, all mapped sequence
reads from the nine samples (VC1–9) with previously
defined mutations in TCN2, MTR, MTRR, MMACHC,
MMADHC, MUT, MMAA and MMAB (Table 1) (11
known and three unknown mutations detected by con-
ventional Sanger sequencing) were inspected blind. Sam-
ples for the validation cohort were selected to include
different types of Cbl deficiency. All the previously
known mutations in all samples were detected in their
correct heterozygous/homozygous state.
The discovery cohort consisted of samples received for
cobalamin genetic diagnosis, for which no mutations
were previously known. Variant changes were identified
in the cobalamin transport genes i.e., TCN1, GIF and
AMN, in genes causing isolated MMA i.e., MMAA,
MUT and MMAB, in genes causing MMA&HC i.e.,
CD320, MMACHC, MMADHC, in genes causing HC
i.e., MTRR, and in two MMA metabolism-related genes
SUCLA2 and ACSF3 (Table 1). Some variants in
MMACHC, MMADHC, MUT, MTRR and ACSF3 were
detected in several samples. In some cases DNA from
blood spots was used in parallel; the coverage compared
to whole blood was similar.
Overall, 33 variations were identified in 12 different
genes. All the new exonic non-synonymous SNVs
(nsSNVs) were predicted to be pathogenic or likely
pathogenic (Additional files 1 and 3).
Among 27 samples with biallelic nucleotide changes, 21
showed at least one described (HGMD® professional re-
lease professional release 2018.1) or one new LoF muta-
tion. Three samples (P6, P9 and P23) presented two new
variants in MUT or SUCLA2. A previously described
functional SNP in TCN1 was detected in two samples (P1
and P2) [4]. Although this disease-associated polymorph-
ism was not detected in the in-house control samples ana-
lysed, this variation is present close to 9% in all data base
consulted (ExAc, gnomAD and Spanish data) with pres-
ence of homozygous cases. Therefore this change alone in
TCN1 is unlikely to be responsible for the clinical picture
in P1 and P2.
P11 (identified by newborn screening) presented the
previously described nonsense mutation p.Arg152Ter
in MUT, plus the disease-associated polymorphism in
TCN1 described above. Both changes were present in
the paternal sample. No other exonic or described in-
tronic mutation were detected. Mean coverage
allowed to rule out a large genomic deletion. It was
not possible to rule out the presence of deep intronic
mutations.
Four patients (P24, P25, P26 and P27) referred for ana-
lysis of genes related to isolated MMA in fact had muta-
tions in ACSF3. After the genetic diagnosis, a slight
increase in urinary malonic acid was confirmed by
GC-MS in three of them.
Functional analysis of the MUT splicing mutation c.1084-
10A > G
The effect of mutation c.1084-10A >G identified in P10 on
the splicing process was addressed using an ex vivo mini-
gene system. The results indicate the insertion of a 9 nt se-
quence upstream of the normal 3′ splice site, as recently
described by transcriptional profile analysis in patient-de-
rived fibroblasts [29]. A shorter transcript was also observed,
resulting from the deletion of 135 nt from exon 6. This was
detected as a heteroduplex along with the normal transcript.
This deletion was generated by the activation of an internal
exonic cryptic 3’splice with a higher splicing score than nor-
mal, plus two exonic splicing enhancer sequences
(Fig. 1).This deletion would likely translate into the elimin-
ation of 45 amino acid residues from the protein.
Functional analysis of SUCLA2 defects in patient-derived
fibroblasts
To assess the bioenergetic profile of patient P23, and to
determine whether mitochondrial function could be
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Table 1 Genetic and biochemical findings of validation and discovery cases
Reference Gene Allele 1 Nucleotide change
(protein effect) HGMD number
Allele 2 Nucleotide change
(protein effect) HGMD number
Clinical and biochemical findings
VC1 TCN2a c.497_498delTC (p.Leu166Profs*7)
CD106933
c.497_498delTC
(p.Leu166Profs*7) CD106933
2 m pancytopenia, FTT, metabolic acidosis.
Improvement after im OHCbl
↑Hcys (pl): 26 μmol/L; ↑C3: 3.4 μmol/L; ↑MMA (ur):
419 mmol/mol creatn
Propionate uptake (FB) (nmol/10 h/mg prot):
Normal
-OHCbl (patient/control): 0.76/0.97
+OHCbl (patient/control): 0.98/0.83
VC2 MTRa c.1348_1349delTCinsGA (p.Ser450Asp) c.3008-4A > G (p.?) CS135282 2 m apnea, somnolence, hypotonia, seizures
↑Hcys (pl): 79 μmol/L; MMA (ur) (N)
VC3 MTRR c.1361C > T (p.Ser454Leu) CM032288 c.1769 + 1G > A
(p.Glu560_Arg590del)
MGA, low serum vit B12; ↑Hcys (pl): 90 μmol/L; N
MMA (ur)
VC4 MMACHC c.271dupA (p.Arg91Lysfs*14) CI055013 c.271dupA (p.Arg91Lysfs*14)
CI055013
NBS: ↑C3 + C3/C2 in DBS
↑Hcys (pl); ↑MMA (ur) > 1000 mmol/mol creatn
VC5 MMACHCa c.271dupA (p.Arg91Lysfs*14) CI055013 c.626dupT (p.Thr210Aspfs*35)
CI095519
NBS: ↑C3 in DBS
↑Hcys: 159 μmol/L; C3 (pl): 8.2 μmol/L; ↑MMA (ur):
608 mmol/mol creatn
Propionate uptake (FB) (nmol/10 h/mg prot):
-OHCbl (patient/control): 0.23/1.90
+OHCbl (patient/control): 2.3/2.34
VC6 MMADHCa c.57_64del8 (p.Ser20*) CD082071 c.57_64del8 (p.Ser20*)
CD082071
4d hypotonia, metabolic acidosis,
hyperammonemia
N Hcys (pl); ↑MMA (ur): 5875 mmol/mol creatn;
Propionate uptake (FB) (nmol/10 h/mg prot):
-OHCbl (patient/control): 0.13/3.31
+OHCbl (patient/control): 2.30/3.37
Mutase (FB):N
VC7 MUTa c.312delC (p.Trp105Glyfs*75) c.1846C > T (p.Arg616Cys)
CM050688
12 m metabolic acidosis
↑MMA (ur): 8810 mmol/mol creatn
VC8 MMAAa c.64C > T (p.Arg22Ter) CM042745 c.433C > T (p.Arg145Ter)
CM042746
5 m metabolic acidosis. Improvement after im
OHCbl
↑MMA (ur)
Propionate uptake (FB) (nmol/10 h/mg prot):
-OHCbl (patient/control): 0.12/1.32
+OHCbl (patient/control): 0.42/2.17
Mutase (FB): N
VC9 MMABa c.548A > T (p.His183Leu) CM154654 c.570_572dupCCG
(p.Arg191dup) CI154655
NBS: ↑C3 in DBS
↑C3 (pl): 7.7 μmol/L; ↑MMA (ur): 830 mmol/mol
creatn
Propionate uptake (FB) (nmol/10 h/mg prot):
-OHCbl (patient/control): 0.63/1.90
+OHCbl (patient/control): 1.19/2.34
Mutase (FB): N
P1 TCN1 c.901G > Tb (p.Asp301Tyr) CM099555 c.901G > Tb (p.Asp301Tyr)
CM099555
Adult with neurological symptoms and low
serum vit B12. Improvement after im OHCbl
↑N Hcys (pl): 17 μmol/L
P2 TCN1 c.901G > Tb (p.Asp301Tyr) CM099555 c.901G > Tb (p.Asp301Tyr)
CM099555
Adult with slight anemia and low serum vit B12.
Improvement after im OHCbl
P3 GIFa c.389C > G (p.Ser130Ter) c.389C > G (p.Ser130Ter) 7y, anemia since 15 m; low serum vit B12.
Improvement after im OHCbl
↑Hcys (pl): 49 μmol/L
P4 AMNa c.514-34G > A (p.Thr172fs) CS127867 c.1046C > A (p.Ser349Ter) 2y, megaloblastic anemia with low serum vit B12.
Improvement after im OHCbl
↑Hcys (pl): 39.9 μmol/L
P5 MMAA c.593_596delCTGA (p.Thr198Serfs*6)
CD043681
c.593_596delCTGA
(p.Thr198Serfs*6) CD043681
↑MMA (ur)
P6 MUTa c.904G > C (p.Ala302Pro) c.904G > C (p.Ala302Pro) NBS: ↑C3 + C3/C2 in DBS
↑MMA (ur): > 1000 mol/mol creatn
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Table 1 Genetic and biochemical findings of validation and discovery cases (Continued)
Reference Gene Allele 1 Nucleotide change
(protein effect) HGMD number
Allele 2 Nucleotide change
(protein effect) HGMD number
Clinical and biochemical findings
Propionate uptake (FB) (nmol/10 h/mg prot)
- > (mut0)
-OHCbl (patient/control): 0.18/1.16
+OHCbl (patient/control): 0.11/1.02
P7 MUTa c.671_678dupAATTTATG
(p.Val227Asnfs*16) CI050942
c.607G > A (p.Gly203Arg)
CM002067
Neonatal presentation
↑MMA (ur)
P8 MUT c.313 T > C (p.Trp105Arg) CM900166 c.2150G > T (p.Gly717Val)
CM920488
7 m metabolic acidosis, lethargy
↑MMA (ur)
P9 MUTa c.2026G > A (p.Ala676Thr) c.2026G > A (p.Ala676Thr) NBS: ↑C3/C2 in DBS
↑C3 (pl): 2.4 μmol/L; ↑MMA (ur): 772 mmol/mol
creatn
Propionate uptake (FB) (nmol/10 h/mg prot)
- > (mut-)
-OHCbl (patient/control): 0.25/1.16
+OHCbl (patient/control): 1.16/1.02
P10 MUTa c.243dupA (p.Pro82Thrfs*2) c.1084-10A > G (p.?) CS128372 ↑MMA (ur)
P11 MUTa
TCN1a
c.454C > T (p.Arg152Ter) CM050671
c.901G > Tb (p.Asp301Tyr) CM099555
? NBS: ↑C3 in DBS
Low serum vit B12; ↑N MMA (ur): 17–58 mmol/
mol creatn
P12 MUT c.671_678dupAATTTATG
(p.Val227Asnfs*16) CI050942
c.671_678dupAATTTATG
(p.Val227Asnfs*16) CI050942
Neonatal presentation and fatal outcome
↑MMA (ur)
P13 MUTa c.1420C > T (p. Arg474Ter) CM050685 c.2026G > A (p.Ala676Thr) NBS: ↑C3/C2 in DBS
↑C3 (pl): 3.4 μmol/L; ↑MMA (ur): 276 mmol/mol
creatn
Propionate uptake (FB) (nmol/10 h/mg prot)
- > (mut-)
-OHCbl (patient/control): 0.28/1.33
+OHCbl (patient/control): 1.13/1.57
P14 MMABa c.220G > T (p.Glu74Ter) c.548A > T (p.His183Leu)
CM154654
NBS: ↑C3/C2 in DBS
↑C3 (pl): 3.64 μmol/L; ↑MMA (ur): 68 mmol/mol
creatn
P15 CD320a c.262_264delGAG (p.Glu88del) CD104789 c.142 + 5G > A (p.?) NBS: ↑C3 + C3/C2 in DBS
↑Hcys (pl): 18.3 μmol/L; N C3 + C4DC (pl); ↑MMA
(ur): 25–170 mmol/mol creatn
P16 MMACHCa c.347 T > C (p.Leu116Pro) CM060067 c.347 T > C (p.Leu116Pro)
CM060067
NBS: ↑C3 + C3/C2 in DBS
↑MMA (ur): 2000 mmol/mol creatn
P17 MMACHCa c.271dupA (p.Arg91Lysfs*14) CI055013 c.271dupA (p.Arg91Lysfs*14)
CI055013
4d: hypotonia, weight loss, vomiting, ↑lac
↑Hcys (pl): 214 μmol/L; ↑C3: 6.5 μmol/L + ↑C4DC
(pl): 0.25 μmol/L
↑MMA (ur): 1197 mmol/mol creatn
P18 MMACHC c.271dupA (p.Arg91Lysfs*14) CI055013 c.271dupA (p.Arg91Lysfs*14)
CI055013
↑Hcys (pl); ↑MMA (ur)
P19 MMADHCa c.748C > T (p.Arg250Ter) CM081188 c.748C > T (p.Arg250Ter)
CM081188
NBS: ↑C3 + C3/C2 in DBS
↑Hcys (pl): 51 μmol/L; ↑C3 (pl): 4.8 μmol/L; MMA
(ur): 290 mmol/mol creatn
P20 MMADHCa c.748C > T (p.Arg250Ter) CM081188 c.748C > T (p.Arg250Ter)
CM081188
NBS: ↑C3 + C3/C2 in DBS
↑Hcys (pl): 59 μmol/L; ↑C3 (pl): 8.5 μmol/L; MMA
(ur): 1175 mmol/mol creatn
P21 MTRR c.1361C > T (p.Ser454Leu) CM032288 c.1361C > T (p. Ser454Leu)
CM032288
17 m; anemia, psychomotor delay
↑Hcys (pl): 76 μmol/L
P22 MTRR c.1361C > T (p.Ser454Leu) CM032288 c.1678_1681delGAGA
(p.Glu560Asnfs*42) CD159487
10 m seizures, megaloblastic anemia
↑Hcys (pl): 89 μmol/L
P23 SUCLA2a c.976G > C (p.Gly326Arg) c.935 T > C (p.Ile312Thr) Hypoglycemia at birth, slight PMD during first
years
Asymptomatic at 11y
↑-N C3(pl): 1–2.2 μmol/L + C4DC
↑N Lac, 3-OHProp, MMA 27 mmol/mol creatn, MC
(ur)
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restored by the transfection of patient-derived fibroblasts
with a lentiviral construct bearing wild-type SUCLA2
cDNA, the oxygen consumption rate (OCR) of control
and patient derived-fibroblasts (transduced or not with
the lentiviral construct) was analyzed. In order to force
the functioning of the electron transport chain, this ex-
periment was performed in a medium supplemented
with galactose. Fig. 2a shows that P23-derived fibroblasts
had a diminished bioenergetic profile compared to
control cells. Basal respiration was significantly reduced
(Fig. 2b). The addition of FCCP to the medium
resulted in increased electron flow through the
mitochondrial respiratory chain and allowed the max-
imum respiration rate to be calculated. Figure 2b
shows this variable to also be significantly reduced in
P23 fibroblasts. Oligomycin-sensitive respiration (OSR),
which represents the ATP-linked oxygen consumption
(Fig. 2c), was also reduced in P23 cells, indicating reduced
oxidative phosphorylation.
The transduction of patient dermal fibroblasts with an
empty construct (Lv-Co) did not influence the bioener-
getic profile, except for an increase in the maximum
respiration rate which was still below control levels.
Transduction with the lentiviral construct bearing
Table 1 Genetic and biochemical findings of validation and discovery cases (Continued)
Reference Gene Allele 1 Nucleotide change
(protein effect) HGMD number
Allele 2 Nucleotide change
(protein effect) HGMD number
Clinical and biochemical findings
Normal carboxylases activities (FB)
Propionate uptake (FB) (nmol/10 h/mg prot) - >
Normal
-OHCbl (patient/control): 0.71/0.75
+OHCbl (patient/control): 0.79/1.13
P24 ACSF3a c.424C > T (p.Gln142Ter) c.1446_1447delCA
(p.Tyr482Ter)
NBS: ↑MMA (ur) since newborn: 512 mmol/mol
creatn
Asymptomatic at 3y
P25 ACSF3a c.1075G > A (p.Glu359Lys) CM116777 c.1075G > A (p.Glu359Lys)
CM116777
5y PMD, bilateral sensorineural hearing loss
AC (pl): N; ↑MMA (ur): 360 mmol/mol creatn
P26 ACSF3a c.1075G > A (p.Glu359Lys) CM116777 c.1672C > T (p.Arg558Trp)
CM116840
Seizures since first months of age
At 12y seizures + dystonia
AC (pl): N; ↑MMA (ur): 124–560 mmol/mol creatn
Normal propionate uptake ± OHCbl (FB)
P27 ACSF3 c.820C > T (p.Gln274Ter) c.820C > T (p.Gln274Ter) NBS: ↑MMA (ur) since newborn. Asymptomatic at
7 m
VC validation case, C3 propionylcarnitine, C2 acetylcarnitine, C4DC methylmalonylcarnitine, DBS dried blood spots, FB fibroblasts, Hcys homocysteine, im
intramuscular, MMA methylmalonic acid, OHCbl hydroxocobalamin, ur urine, pl plasma, Lac Lactate, MC methylcitrate, NBS newborn screening, PMD
psychomotor delay
aMutations confirmed in parents; b Variant with uncertain clinical significance; new mutations in bold
Mutations named according to GenBank accession number included in Additional file 3: Table S1
Fig. 1 Functional analysis of c.1084-10G > A identified in the MUT gene. Splicing pattern observed in the minigene construct bearing the empty
vector (pSPL3), normal minigene (c.1084-10G), and mutant vector c.1084-10G. The figure shows the splicing scores obtained using the Human
Splicing Finder (www.umd.be/HSF3/). The ESE sequences were obtained using RESCUE-ESE software (www.genes.mit.edu/burgelab/rescue-ese)
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wild-type SUCLA2 cDNA, however, was able to restore
the bioenergetic profile (Fig. 2a). Both basal and max-
imal respiration rates were restored to control levels
(Fig. 2b). As shown in Fig. 2c, oligomycin-sensitive res-
piration was also significantly increased, suggesting the
restoration of oxidative phosphorylation. These results
indicate that the bioenergetic deficit observed in the
cells from P23 could be caused by defects in SUCLA2.
In silico estimates of the functional impact of missense
variants
Structural analysis of the SUCLA2 variants was per-
formed for prediction of protein dysfunction at the mo-
lecular level.
The functional and in silico analyses of the two
SUCLA2 variants also suggested them to be damaging.
Only AlignGVGD gave a nearly neutral score for
p.Ile312Thr. It should be noted that the pathogenicity
score for this variant was closer to the threshold be-
tween neutral and damaging replacements, suggesting a
milder effect (Additional file 1). This observation agrees
with the results of the structural analysis. The wild type
residues Gly326 and Ile312 were identified in a hom-
ology model of SUCLA2, obtained using pig SUCLG2.
Visual analysis of the structures (Fig. 3) showed that
both loci fell near the protein’s “phosphate shuttle” loop
[18], indicating that the replacement of the wild-type
residue might interfere with the functional role of this
loop. This was particularly noticeable for Gly326, which
lies in close contact with residue His299 of the loop, and
occurs at a packed location in the structure. The re-
placement of glycine by the bulkier arginine would un-
doubtedly create some steric clashes. Gly326 was found
to be highly conserved in multiple sequence alignments
of the SUCLA2 family, supporting the idea that it may
Fig. 2 Functional rescue of mitochondrial dysfunction. Bioenergetic profiles of SUCLA2 in patient P23 fibroblasts transduced with a lentiviral
plasmid bearing wild-type SUCLA2 cDNA (Lv Wt) or a null construct (Lv Co), and control-derived fibroblasts. Experiments were performed using a
Seahorse XF device. A Oxygen consumption rates of control and patient fibroblasts were measured in DMEM with galactose (1 g/L) instead of
glucose, and upon the subsequent addition of a 6 μM oligomycin, b 50 μM FCCP, c 1 μM rotenone or, d 1 μM antimycin. B Basal and maximum
respiration (Rmax) were calculated for each situation. C Oligomycin-sensitive respiration (OSR) was calculated as the difference between the basal
respiration and the oxygen consumption rate measured as described in (C), after the addition of 6 μM oligomycin. The results reflect the mean of
three biological repetitions. Control values are the mean for two different control cell lines. (*p < 0.05; **p < 0.01; ***p < 0.001 [Student t test])
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have a functional role. Finally, Ile312 was involved in a
dense network of residue interactions, although no close
contact (<5Angs) with the residues from the functional
“phosphate shuttle” loop was observed. This indicates,
once again, that replacement of Ile312 may have a
milder impact on function. This agrees with the less
strict conservation pattern seen in multiple sequence
alignments. In summary, agreement was seen between in
silico predictions and structural analyses for both vari-
ants, indicating that the observed replacements are
pathogenic, although p.Gly326Arg probably causes more
severe problems than p.Ile312Thr.
Discussion
The gold standard for coming to genetic diagnoses of
cobalamin defects has for some time been gene-by-gene
Sanger sequencing of individual DNA fragments. En-
zymatic and cellular methods are employed before such
sequencing to help in the selection of the gene defects
to be sought, but this is time-consuming and laborious
[1]. Further, no biochemical methods have been available
to test for cobalamin absorption and transport defects,
and while plasma B12 concentrations are tentatively used
to help in the selection of genes to be sequenced, this
has probably led to the under-recognition of cases [34].
This costly, stepwise, and time-consuming methodology
is gradually being replaced by NGS technologies, which
offer higher throughput and scalability, cost less per se-
quenced nucleotide and have shorter turnaround times
[35]. The present work reports the NGS analysis of a co-
hort of patients suspected of having cobalamin defects
(plus the corresponding structural/functional analyses
for some of the defects involved) and shows it to be
quick and reliable.
A 100% correct diagnostic rate was returned with the
validation cohort, with exonic and intronic nucleotide
changes and small deletions (c.271dupA in MMACHC
or c.57_64del8 in MMADHC) all successfully detected.
With the clinical exome massive parallel sequencing sys-
tem used, the depth and breadth of coverage of the co-
balamin metabolism-related genes was > 30× and 99%
respectively. The sensitivity and specificity of the method
appeared to be very good and the results reproducible
(several mutations were detected in more than one unre-
lated mutant allele i.e., c.271dupA in MMACHC,
c.671_678dupAATTTATG in MUT, c.748C > T in
MMADHC etc.). Thus, even though the use of smaller,
specific panels is recommended [36] so that secondary
incidental findings are avoided, the present work shows
clinical exome sequencing to be successful. It could be
used in sequencing analyses of single patients as well
groups of patients whose members have other, unrelated
disorders.
The LoF mutations detected in GIF and AMN were
found to affect the absorption of cobalamin. GIF and
AMN, in addition to CUBN and TCN1, are not usually
captured in the available panels offered by genetic com-
panies but the results reported in the present work have
demonstrated they should be analyzed [19, 34].
Fig. 3 Structure and conservation analysis of SUCLA2 variants (p.G326R, p.I312T). For each variant, p.G326R (a) or p.I312T (b), the location of the
wild-type amino acid (red) and its network of interactions (light orange) are shown. Close residue-residue contacts are drawn with dashed lines.
The “phosphate shuttle” loop is marked in dark orange [44]. The conservation pattern for each variant is represented below the structural models.
The size of the letters reflects the degree of conservation
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The potential missense changes p.Ala302Pro and
p.Ala676Thr, identified in MUT, were predicted to be
damaging by several bioinformatic algorithms. The
present detection of the associated mutations in combin-
ation with functional cellular studies provided a rational
basis for tailored treatment. Indeed, the cellular uptake
of 14C-propionate revealed that p.Ala302Pro is a mut0
mutation, while p.Ala676Thr located in the C-terminal
of the cobalamin binding domain is likely a mut− muta-
tion. Based on these results, patient P6 might not be re-
sponsive to the pharmacological administration of the
vitamin, while P9 would likely respond. Case P11 inher-
ited a described LoF mutation in MUT and the func-
tional polymorphism p.Asp301Tyr in TCN1, probably an
incidental finding of no clinical significance. This asymp-
tomatic individual was detected in newborn screening.
No other mutations were detected in the coding region
of MUT, not even in the deep intronic sequence re-
ported to bear an intronic pathogenic mutation [30, 37].
Although massive parallel sequencing exome analysis
cannot rule out the presence of other nucleotide changes
in promoter or intronic sequences, both the absence of
clinical symptoms and the slight abnormal levels of urin-
ary MMA in case P11 suggested he/she was a carrier of
the disease.
Variations in genes that do not encode cobalamin
metabolism-related proteins (ASCF3 and SUCLA2) were
also detected in the present work. Both were associated
with slightly increased urinary MMA. The two new vari-
ants of SUCLA2 (p.Gly326Arg and p.Ile312Thr) detected
are probably damaging changes; both were predicted to
be so in bioinformatic and structural analyses. Neither
was found to be present in database control populations
nor in the in-house control samples. Structural analysis
suggested that the replacement of Ile312 may have a
mild functional impact, which agrees with the less strict
conservation pattern seen in multiple sequence align-
ments. Importantly, the mitochondrial dysfunction in
deficient fibroblasts from P24 was rescued via the stable
expression of the SUCLA2 protein through lentiviral
transduction. This suggests that SUCLA2 is the gene
likely affected in this patient, although his/her symptoms
were atypical [18, 38]. With respect to ASCF3, individ-
uals P24, P25, P26 and P27 were diagnosed as having
isolated MMA since the urinary malonic acid that iden-
tifies CMAMMA can be easily missed [39]. Given the
difficulty in diagnosing CMAMMA, several of the
present patients were originally diagnosed during genetic
analyses, e.g., exome sequencing [40]. Even though a
new method for the rapid metabolic diagnosis of
CMAMMA has recently been reported [39], diagnoses
by genetic analysis would be improved by second tier
genetic testing after newborn screening. In some cases
ACSF3 defects only cause biochemical conditions such
as short-chain acyl-CoA dehydrogenase deficiency [41]
or 3-methylcrotonylglycinuria [42], and symptoms ap-
pear only during viral infections etc. [39, 43]. In other
cases, as reported in the present work, patients can show
neurological damage [19]. Prompt diagnosis would avoid
unnecessary treatment with vitamin B12.
The use of massive parallel sequencing in a new era of
newborn screening would avoid the time-consuming
biochemical and enzymatic methods presently used to
help identify which genes might be causing isolated
MMA, MMA&HC, HC or CMAMMA. The rapid return
of an accurate genetic diagnosis would allow the pre-
scription of an appropriate treatment just a few days
after birth. This report illustrates the clinical usefulness
of massive parallel sequencing in the diagnosis of cobala-
min and related defects. This powerful technology could
improve the detection of these under-recognized or rare
vitamin B12 defect conditions.
Conclusions
This work provides evidence supporting the use of
massive parallel sequencing as second tier test for con-
firming cobalamin defects following their detection in
newborn screening. Biochemical and cellular analyses
and additionally comprehensive phenotyping are needed
for an accurate classification of variants for making fully
useful clinical reports.
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